ICU Medical Inc (NASDAQ: ICUI) has confirmed the schedule for its second quarter 2026 financial results, setting the stage for investors to review the medical device manufacturer’s performance in the global infusion systems market. The San Clemente-based company will release its earnings on Thursday, August 6, 2026, at approximately 4:00 p.m. ET (1:00 p.m. PT). This announcement provides clarity on when stakeholders can access critical data regarding the firm’s operations in hospital, alternate site, and home care settings.

The conference call to discuss these results is scheduled for 4:30 p.m. ET (1:30 p.m. PT) on the same day, Thursday, August 6, 2026. Participants can access the call by dialing 1-800-420-1459 and using the conference ID "ICUMED". The event underscores the company’s commitment to transparent communication with its shareholder base regarding its strategic execution in critical care products.

Access Details

In addition to the telephone line, the conference call will be broadcast simultaneously via webcast. Investors can access this stream by visiting www.icumed.com , navigating to the Investors tab, and selecting the Webcast icon. A replay of the webcast will also be available for those unable to attend the live session.

About ICU Medical

ICU Medical operates as a global leader in the development, manufacture, and sale of innovative medical products. Its portfolio focuses on infusion systems, infusion consumables, and high-value critical care products designed for use in diverse clinical environments. Headquartered in San Clemente, California, the company emphasizes quality, innovation, and value delivery to its clinical customers worldwide.

For further information, investors may contact Brian Bonnell, Chief Financial Officer of ICU Medical Inc, at (949) 366-2183. Media inquiries are directed to John Mills, Managing Partner at ICR Inc, reachable at (646) 277-1254.

BTIG analyst Sam Eiber has initiated coverage on ICU Medical Inc with a Buy rating and a price target of $170, suggesting an upside from the previous closing price of $142.20. The new rating highlights a positive stance on the medical technology company's stock potential based on its market position and growth prospects. This initiation is part of a broader set of analyst ratings updates affecting multiple firms.

Coverage Details

The initiation of coverage comes with a specific price target set at $170. This target suggests an upside from current trading levels, indicating confidence in the company's future performance. The rating is intended to guide investors considering the stock.

Analyst Recommendation

Sam Eiber, the analyst at BTIG, assigned the Buy rating based on the firm's assessment of ICU Medical's market position and growth prospects.